Global Perspectives on Leukemia in 2021 and Beyond
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
FACULTY MEMBERS
Charles Mullighan, MD, FRACP, MBBS
St. Jude Children’s Research Hospital, Memphis, TN, USA
Naval Daver, MD, FRACP, MBBS
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Jorge Cortes, MD
Georgia Cancer Center, Augusta, GA, USA
Rami Komrokji, MD
H. Lee Moffit Cancer Center, Tampa, FL
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, , USA
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Jerry Radich, MD
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Neil Shah, MD, PhD
University of California, San Francisco, CA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- CML: First-Line Treatment
- CML: Treatment of Resistant/Refractory Patients and New Targets
- ALL: Genetic Subsets
- ALL: Role of Monoclonal and Bispecific Antibodies
- ALL: Role of CAR T Cells
- MDS: Low-Risk Disease
- MDS: High-Risk Disease
- AML: Newly Diagnosed Patients (including FLT3 and IDH1/2 mutated disease)
- AML: Relapse/Refractory Patients (including FLT3 and IDH1/2 mutated disease)
